11 Jan 2020
Antibiotic Combination Therapy Against Resistant Bacteria Infections: Synergy, Rejuvenation & Resistance Reduction
Anti-Microbial Resistance (AMR) is a pandemic which threatens modern medicine. There is a lack of effective drug treatment due to the slow pace, high cost and low achievable sales prices...
16 Oct 2019
Are New Antibiotic Combinations The Solution To The AMR Crisis?
Combinations of old antimicrobials such as Helperby’s colistin and azidothymidine are a possible alternative to developing new chemical entities, because they cost one tenth of the price. A Global...
26 Feb 2019
WHO Recognises Antimicrobial Resistance As One Of The Most Pressing Global Threats To Medicine
26 Sep 2018
The Drugs Don’t Work
The fight against antibiotic resistance is real and something we all have a responsibility in tackling. As traditional drugs stop working, what steps are being taken now?...
27 Jul 2018
Outsmarting The World’s Most Dangerous Superbugs
Using its antibiotic renewable technology, Helperby Therapeutics is developing a new class of antibiotics with activity against multi drug-resistant bacteria, including strains with transferable resistance to carbapenems and colistin....
21 Jul 2018
Antibiotics & Antimocrobial Resistance (AMR) - A Global Perspective
Antibiotic resistance is at a crossroad. In the world today, deaths in low income countries from Antimicrobial Resistance (AMR) are predicted to rise dramatically by 2050. We know how to stop...
15 Jun 2018
Journal for Clinical Studies Reports Helperby’s Phase 1 Results in Brand New Antibiotic
The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority Pathogens. In addition,...
15 Jun 2018
Helperby Therapeutics’ Combination Antibiotic Therapy is Effective Against WHO Critical Priority Pathogen in Phase I Study
Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE),...
1 Jun 2018
BusinessWire Feature Phase 1 Results for New Critical Priority Antibiotic from Helperby Therapeutics
The combination is azidothymidine (AZT), a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority Pathogens. AZT and colistin act synergistically against...
